

Cover Story
SWOG earlier this week started to accrue patients to Lung-MAP, a clinical trial for second-line treatment of non-small cell lung cancer.
By Tessa Vellek
In Brief


Trending Stories
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - California Institute of Regenerative Medicine and Cancer Research: A promise broken?
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Lou Weiner to step down as director of Georgetown’s Lombardi CCC after 18 years
- After a year, Stephenson institute sees a broader role in funding pancreatic cancer research, fostering collaborations
“We are not just funding research. We are building a trusted community.”










